Home›US Markets›Sectors›Biopharma stocks slide after Novartis Lp(a) drug trial…

Biopharma stocks slide after Novartis Lp(a) drug trial failure

The selloff follows concerns that Lp(a) lowering may not deliver the hoped for reduction in some fatal cardiovascular events.

Reported · Written up by our desk · Sectors

Novartis has suffered a failed trial for a cholesterol-related drug targeting Lp(a), and the setback helped trigger a broad selloff across biopharma stocks, MarketWatch reports.

The company, along with several other drugmakers, had been betting that lowering Lp(a) would reduce the risk of sometimes fatal cardiovascular events.

More like this

Sources